![]() |
市场调查报告书
商品编码
1933388
全球凝血分析仪市场:市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测(2026-2034)Coagulation Analyzers Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
预计2025年全球凝血分析仪市场规模将达39亿美元,2026年成长至41.2亿美元,最终在2034年达到66.5亿美元,预测期间内复合年增长率(CAGR)为6.16%。北美地区将引领市场,2025年市场占有率将达到35.47%,这主要得益于其完善的医疗保健基础设施、血液疾病盛行率的上升以及先进凝血检测设备的日益普及。
凝血分析仪是一种用于测量血液凝固能力和凝固速度的医疗检测设备。 它们对于监测接受华法林等抗凝血治疗的患者以及检测包括血友病在内的凝血相关疾病至关重要。心血管疾病和血栓形成的发病率上升,以及外科手术数量的增加,正在推动对这些分析仪的需求不断增长。西门子医疗、希森美康、罗氏和沃芬等主要市场参与者正在积极推出产品、建立合作关係,以巩固其市场地位。
市场动态
市场驱动因素
血液疾病盛行率上升
凝血相关疾病(尤其是血友病)发病率的上升,以及人口老化和不健康生活方式的增加,正在推动对凝血检测的需求。医院和诊断实验室扩大采用自动化凝血分析仪,以实现准确、快速和可靠的诊断,并改善患者的治疗效果。 此外,对即时检测 (POC) 的需求不断增长,正在改善接受抗凝血治疗患者的检测可及性。根据珀斯血液研究所的数据,截至 2025 年 7 月,全球血友病患病率约为每 6,000 至 10,000 名男性中就有 1 例,其中 A 型血友病的盛行率为每 5,000 人中 1 例,B 型血友病的患病率为每 30,000 人中 11 例。
市场限制因子
先进系统和试剂成本高
自动化凝血分析仪的普及受到高昂的初始投资和维护成本的限制。具备多参数检测、自动化和连接功能的先进型号价格昂贵,而持续的试剂和校准成本进一步增加了营运成本。在资源有限的环境中,实验室往往依赖手动或半自动系统,这限制了效率和准确性,从而减缓了市场渗透。
市场机会
个人化医疗与新一代分析设备
个人化抗凝血治疗,包括华法林和直接口服抗凝血剂 (DOAC) 的个人化剂量,推动了对精准凝血监测的需求。基因谱分析和基于人工智慧的预测分析的整合,正在提升个性化患者护理水平,并为三级医疗中心和研究机构的新一代凝血分析仪创造了丰厚的市场机会。
市场趋势
转型为全自动化和即时侦测 (POC) 系统
医疗机构正扩大采用高通量、全自动分析仪进行即时多参数检测,以减少人为误差。同时,用于急救和快速检测的便携式即时检测分析仪的需求也在不断增长。 例如,2021年10月,Trivitron Healthcare和Diagon-Vanguard Diagnostics在印度推出了一系列凝血分析仪,透过自动化、易操作性和内建的品质控制功能,为临床决策提供支援。
市场挑战
熟练实验室技术人员短缺
新兴市场面临训练有素的实验室技术人员短缺的问题,这些技术人员需要操作复杂的分析仪、进行校准并确保品质控制。这种人才短缺降低了效率,限制了利用率,并影响了诊断准确性。世界卫生组织预测,到2030年,全球将出现1,100万医护人员缺口,主要集中在低收入和中低收入国家,这将影响市场扩张。
依产品划分
市场依系统(自动化、半自动化和手动)和耗材细分。 由于自动化系统需要使用特定试剂,耗材部分预计在2026年将占31.71%的市占率。系统部分预计将以5.8%的复合年增长率成长。
依技术划分
光学检测凭藉其准确性和可重复性,在2025年占市场主导地位,预计在2026年将占60.64%的市场占有率。机电检测预计将以6.3%的复合年增长率成长。
依侦测类型划分
凝血酶原(PT)检测部分预计将在2025年占最大的市场占有率,并在2026年保持30.87%的市场占有率,这主要归功于其在监测抗凝血治疗和诊断凝血障碍方面的重要作用。 D-二聚体检测预计将以6.3%的复合年增长率成长。
依最终使用者划分
医院在2025年占市场主导地位,并在2026年维持38.13%的市占率。这主要归功于分析设备的高普及率和庞大的患者群体。预计诊断实验室的复合年增长率将达到6.5%。
北美市场在2025年将达到13.8亿美元,预计到2026年将增长至14.6亿美元,这主要得益于其完善的医疗保健基础设施以及美国超过6000家医院。
预计欧洲市场在2025年将达到11.6亿美元,主要得益于其大量的诊断实验室。 预计到 2026 年,英国、德国和法国的市场规模将分别达到 2.3 亿美元、2.8 亿美元和 1.9 亿美元。
预计到 2025 年,亚太地区的市场规模将达到 11 亿美元,而到 2026 年,印度和中国的市场规模将分别达到 1.4 亿美元和 4.7 亿美元。到 2025 年,拉丁美洲和中东及非洲地区的市场规模将分别达到 1.6 亿美元和 8,000 万美元。
The global coagulation analyzers market was valued at USD 3.90 billion in 2025 and is projected to grow to USD 4.12 billion in 2026, ultimately reaching USD 6.65 billion by 2034, reflecting a CAGR of 6.16% during the forecast period. North America dominated the market in 2025 with a 35.47% share, driven by the presence of well-established healthcare infrastructure, rising prevalence of hematological disorders, and the increasing adoption of advanced coagulation testing devices.
Coagulation analyzers are medical laboratory instruments that measure how well and how quickly blood clots. They are critical for monitoring patients on anticoagulant therapies, such as warfarin, and for detecting coagulation-related disorders, including hemophilia. The rising incidence of cardiovascular diseases, thrombosis, and increasing surgical procedures have accelerated the demand for these analyzers. Major market players, such as Siemens Healthineers AG, Sysmex, F. Hoffmann-La Roche Ltd., and Werfen, are actively engaged in product launches, partnerships, and collaborations to strengthen their market presence.
Market Dynamics
Market Drivers
Rising Prevalence of Hematological Disorders
The increasing incidence of coagulation-related disorders, particularly hemophilia, and an aging population with unhealthy lifestyles have intensified the demand for coagulation testing. Hospitals and diagnostic laboratories are increasingly adopting automated coagulation analyzers to enable accurate, rapid, and reliable diagnosis, improving patient outcomes. Additionally, the growing demand for point-of-care (POC) testing enhances accessibility for patients undergoing anticoagulant therapy. According to the Perth Blood Institute, as of July 2025, the global prevalence of hemophilia was approximately 1 in 6,000-10,000 males, with hemophilia A affecting 1 in 5,000 and hemophilia B affecting 1 in 30,000.
Market Restraints
High Cost of Advanced Systems and Reagents
The adoption of automated coagulation analyzers is hindered by high capital and maintenance costs. Advanced models with multi-parameter testing, automation, and connectivity features are expensive, and recurring reagent and calibration costs further increase operational expenditures. In low-resource settings, laboratories often rely on manual or semi-automated systems, which limits efficiency and accuracy, slowing market penetration.
Market Opportunities
Personalized Medicine and Next-Generation Analyzers
Tailored anticoagulant therapies, including individualized dosing of warfarin and direct oral anticoagulants, drive the need for precise coagulation monitoring. Integration with genetic profiling and AI-enabled predictive analytics is enhancing personalized patient care, creating lucrative opportunities for next-generation coagulation analyzers in tertiary hospitals and research institutions.
Market Trends
Shift to Fully Automated and Point-of-Care Systems
Healthcare facilities increasingly prefer high-throughput, fully automated analyzers for real-time, multi-parameter testing, reducing human error. Simultaneously, portable POC analyzers are gaining traction for emergency care and rapid testing. For example, in October 2021, Trivitron Healthcare and Diagon-Vanguard Diagnostics launched a range of coagulation analyzers in India, supporting clinical decision-making with automation, ease of operation, and built-in quality control.
Market Challenges
Shortage of Skilled Laboratory Personnel
Emerging markets face a shortage of trained laboratory staff to operate complex analyzers, conduct calibration, and ensure quality control. This staffing gap reduces efficiency, limits utilization, and affects diagnostic accuracy. The WHO projects a global healthcare workforce shortfall of 11 million by 2030, mainly in low- and lower-middle-income countries, impacting market expansion.
By Product
The market is divided into systems (automatic, semi-automatic, manual) and consumables. The consumables segment accounted for 31.71% share in 2026, driven by the adoption of automated systems requiring system-specific reagents. The systems segment is projected to grow at a CAGR of 5.8%.
By Technology
Optical detection dominated in 2025 due to its accuracy and reproducibility, holding a 60.64% share in 2026. Electromechanical detection is projected to grow at a CAGR of 6.3%.
By Test Type
The prothrombin (PT) test segment captured the largest share in 2025 and is projected to hold 30.87% in 2026, due to its critical role in monitoring anticoagulant therapy and diagnosing coagulation disorders. D-dimer testing is expected to grow at a CAGR of 6.3%.
By End-User
Hospitals dominated in 2025 and held a 38.13% share in 2026, owing to higher installation rates of analyzers and large patient inflows. Diagnostic laboratories are projected to grow at a CAGR of 6.5%.
North America led with USD 1.38 billion in 2025, growing to USD 1.46 billion in 2026, supported by established healthcare infrastructure and over 6,000 hospitals in the U.S.
Europe reached USD 1.16 billion in 2025, driven by numerous diagnostic laboratories, with the U.K., Germany, and France at USD 0.23 billion, USD 0.28 billion, and USD 0.19 billion in 2026.
Asia Pacific was valued at USD 1.10 billion in 2025, with India and China at USD 0.14 billion and USD 0.47 billion in 2026. Latin America and Middle East & Africa reached USD 0.16 billion and USD 0.08 billion, respectively, in 2025.
Competitive Landscape
Key market players include Siemens Healthineers AG, Sysmex, F. Hoffmann-La Roche Ltd., Werfen, Helena Laboratories, Beckman Coulter, Meril Life Sciences, HORIBA, BIOLABO, and Diagon. Companies focus on new product launches, partnerships, and global expansion to maintain market leadership. Recent developments include:
Conclusion
The global coagulation analyzers market is expected to grow from USD 4.12 billion in 2026 to USD 6.65 billion by 2034, driven by rising prevalence of hematological disorders, adoption of automated and POC analyzers, and the shift toward personalized medicine. North America dominates the market, while Europe and Asia Pacific exhibit significant growth potential. Challenges such as high system costs and skilled workforce shortages remain, but technological advancements and integration with AI and genetic profiling continue to offer lucrative opportunities for market expansion.
Segmentation By Product, Technology, Test Type, End-user, and Region
By Product * Systems
By Technology * Optical Detection
By Test Type * Prothrombin
By End-user * Hospitals
By Region * North America (By Product, Technology, Test Type, End-user, and Country)